Dendritic Cell (DC) therapy represents a new and promising immunotherapeutic approach for treatment of advance cancer as well as for secondary prevention of cancer. As Dr. Harmon Eyre, the VP of Research at the AMA commented on results of DC therapy for cancer: “Patients' responses are far out of proportion to anything that any current therapy could do”. For decades, cancer researchers have been interested in immunologic treatment using vaccines against cancer but with little progress. However, recent advances in recognition of the importance of 1) tumor associated antigens that can be used to vaccinate patients, and 2) the dendritic cell as a potent blood cell to present such antigens and stimulate the naïve immune system together leads to successful implementation of Dendritic Cell therapy with reports of complete responses even in stage IV cancer patients who have failed all other therapies. Dendritic Cell (DC) Therapy or so-called Dendritic Cell vaccine is a newly emerging and potent form of immune therapy used to treat cancer, AIDS and other serious conditions. In case of cancer, Dendritic Cell therapy is an immune therapy which harnesses the body's own immune system to fight cancer. The Dendritic Cell itself is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells in the effector arm of the immune system. Although Dendritic Cells are potent cells, they are not usually present in adequate quantity to allow for a potent immune response. Dendritic Cell Therapy thus involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce Dendritic Cells which are then given back to a patient in order to allow massive Dendritic participation in optimally activating the immune system. To learn more about vaccine and Dendritic Cell therapy for cancer, please read the following: